Phase 2
N=274
Efficacy and Safety Evaluation of Anti-Caries Varnish
Dental Caries in Children
Bottom Line
View on ClinicalTrials.gov: NCT04947527 ↗Enrolled (actual)
274
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcome: Primary: Caries Increment — 9.8; 11.3 Number of tooth surfaces — p=0.279
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Test varnish (Drug); Placebo (Drug)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Advantage Silver Dental Arrest, LLC
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Caries Increment |
9.8; 11.3 | 0.279 |
| PRIMARY Number of Participants With Caries, Surfaces Missing Due to Caries or Filled Surfaces |
53; 72 | 0.023 sig |
| SECONDARY Adverse Events |
42; 58 | 0.133 |
Summary
The purpose of the study is to determine the efficacy & safety of Advantage Anti-Caries Varnish for primary prevention. The objectives are:
1) To determine if Advantage Anti-Caries Varnish (test varnish) is superior to an active control varnish (5% Sodium Fluoride, no Povidone-Iodine) in the prevention of caries lesions in the primary dentition. Specifically, prevention of caries lesions in primary teeth that either are sound, have only d1 (white spots) lesions or unerupted at baseline; and 2) To document the safety of the test varnish.
Eligibility Criteria
Inclusion Criteria
- The subject's parent or legal guardian must provide signed and dated informed consent (parent permission form).
- The subject's parent or legal guardian of the subject must be willing and able to comply with study requirements.
- The subject is a 6-24 months at the time of enrollment.
- The subject must be in good general health as evidenced by parent report.
- The subject will have at least 1 erupted tooth that is either sound or has only a d1 (white spots) lesion.
Exclusion Criteria
- Previous treatment with fluoride varnish
- Known allergy to iodine
- Diagnosis of thyroid disease
- Chronic, prophylactic use of antibiotics
- Treatment with another investigational drug or intervention within 30 days preceding the Baseline Visit.
- Visible cavities (d2-4)
- Presence of intraoral pathology that would make assessment of post treatment soft tissue ulcerations or inflammation impossible (child could be enrolled if problem is treated and lesions cleared)
- Parent anticipates the child will move from Pohnpei during the next 2 years.
Data sourced from ClinicalTrials.gov (NCT04947527). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.